Results 71 to 80 of about 755,388 (347)

The Lived Experience of Ovarian Cancer [PDF]

open access: yes, 2011
It was estimated that in 2009,21,550 women would be diagnosed with ovarian cancer and 14.600 women would die from it. There are approximately 176,007 women living with ovarian cancer in the US.
Tyll, Jennifer
core   +1 more source

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]

open access: yes, 2016
Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi   +130 more
core   +1 more source

Gonadotropins and Ovarian Cancer [PDF]

open access: yesEndocrine Reviews, 2007
Ovarian epithelial cancer (OEC) accounts for 90% of all ovarian cancers and is the leading cause of death from gynecological cancers in North America and Europe. Despite its clinical significance, the factors that regulate the development and progression of ovarian cancer are among the least understood of all major human malignancies.
Wong, AST   +3 more
openaire   +4 more sources

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

open access: yesMolecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan   +9 more
wiley   +1 more source

CAMKKβ supports growth and viability of epithelial ovarian cancer in vitro and in vivo

open access: yesScientific Reports
Epithelial ovarian cancer (EOC) metastasizes predominantly through multicellular aggregates known as spheroids, which disseminate within the peritoneal cavity and initiate secondary disease upon reattachment at distant sites.
Matthew J. Borrelli   +5 more
doaj   +1 more source

Global Deletion of Trp53 Reverts Ovarian Tumor Phenotype of the Germ Cell–Deficient White Spotting Variant (Wv) Mice

open access: yesNeoplasia: An International Journal for Oncology Research, 2015
White spotting variant (Wv) mice are spontaneous mutants attributed to a point mutation in the c-Kit gene, which reduces the tyrosine kinase activity to around 1% and affects the development of melanocytes, mast cells, and germ cells.
Kathy Qi Cai   +6 more
doaj   +1 more source

Deciphering the Importance of Glycosphingolipids on Cellular and Molecular Mechanisms Associated with Epithelial-to-Mesenchymal Transition in Cancer

open access: yesBiomolecules, 2021
Every living cell is covered with a dense and complex layer of glycans on the cell surface, which have important functions in the interaction between cells and their environment.
Cécile Cumin   +3 more
doaj   +1 more source

Niraparib in ovarian cancer. results to date and clinical potential [PDF]

open access: yes, 2017
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both ...
Benedetti Panici, Pierluigi   +5 more
core   +1 more source

Epithelial ovarian cancer [PDF]

open access: yesThe Lancet, 2019
Epithelial ovarian cancer generally presents at an advanced stage and is the most common cause of gynaecological cancer death. Treatment requires expert multidisciplinary care. Population-based screening has been ineffective, but new approaches for early diagnosis and prevention that leverage molecular genomics are in development.
S, Lheureux   +3 more
openaire   +3 more sources

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy